West Pharmaceutical Services, Inc. (WST) — Financial statements
Income statement, balance sheet, and cash flow for West Pharmaceutical Services, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3,074↑6.3% | 2,893↓2.0% | 2,951↑2.3% | 2,886↑1.9% | 2,831 | |
| Cost of Revenue | 1,970↑4.2% | 1,891↑4.0% | 1,818↑4.1% | 1,747↑5.4% | 1,657 | |
| Gross Profit | 1,103↑10.1% | 1,002↓11.5% | 1,133↓0.5% | 1,139↓2.9% | 1,173 | |
| Operating Expenses | ||||||
| R&D Expenses | 74↑7.5% | 69↑1.0% | 68↑16.9% | 59↑10.8% | 53 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 393↑16.1% | 339↓4.2% | 353↑11.5% | 317↓12.4% | 362 | |
| Other Expenses | 19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 486↑19.2% | 408↓3.4% | 422↑12.4% | 375↓9.5% | 415 | |
| Total Costs & Expenses | 2,456↑6.9% | 2,298↑2.6% | 2,240↑5.6% | 2,122↑2.4% | 2,072 | |
| Operating Results | ||||||
| Operating Income | 617↑3.8% | 595↓16.4% | 711↓6.9% | 764↑0.6% | 759 | |
| Depreciation & Amortization | 124↓19.9% | 155↑13.2% | 137↑13.8% | 121↓1.4% | 122 | |
| EBITDA | 724↓2.7% | 744↓11.9% | 844↑4.5% | 808↓8.1% | 880 | |
| EBIT | 599↑1.8% | 588↓16.8% | 707↑2.8% | 688↓9.2% | 757 | |
| Interest & Other Income | ||||||
| Net Interest Income | 17↑2.4% | 17↓13.0% | 19↑868.0% | -3↑66.7% | -8 | |
| Interest Income | 18↓9.7% | 20↓30.0% | 28↑449.0% | 5↑410.0% | 1 | |
| Interest Expense | 0.60↓79.3% | 3↓67.0% | 9↑15.8% | 8↓10.6% | 9 | |
| Non-Operating Income | 18↑193.5% | 6↑51.2% | 4↓94.6% | 76↑5746.2% | 1 | |
| Other Income / Expenses | -2↓137.5% | 6↑16.7% | 5↑107.6% | -63↓710.7% | 10 | |
| Income Before Tax | 615↑2.5% | 600↓16.1% | 716↑2.2% | 701↓8.9% | 769 | |
| Income Tax Expense | 122↑13.1% | 108↓12.1% | 122↑6.6% | 115↑7.0% | 107 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 494↑0.2% | 493↓17.0% | 593↑1.3% | 586↓11.5% | 662 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 494↑0.2% | 493↓17.0% | 593↑1.3% | 586↓11.5% | 662 | |
| Bottom-Line Net Income | 494↑0.2% | 493↓17.0% | 593↑1.3% | 586↓11.5% | 662 | |
| EPS (Basic) | 6.83↑1.2% | 6.75↓15.5% | 7.99↑1.4% | 7.88↓11.5% | 8.90 | |
| EPS (Diluted) | 6.80↑1.6% | 6.69↓15.1% | 7.88↑1.9% | 7.73↓10.8% | 8.67 | |
| Weighted Average Shares | 72↓1.0% | 73↓1.7% | 74↓0.1% | 74↑0.0% | 74 | |
| Weighted Average Diluted Shares | 73↓1.4% | 74↓2.1% | 75↓0.7% | 76↓0.7% | 76 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.